Artelo Biosciences, Inc. (ARTL)
| Market Cap | 1.73M -47.9% |
| Revenue (ttm) | n/a |
| Net Income | -13.47M |
| EPS | -28.02 |
| Shares Out | 938.13K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,610,399 |
| Open | 2.240 |
| Previous Close | 2.340 |
| Day's Range | 1.770 - 2.340 |
| 52-Week Range | 1.770 - 85.800 |
| Beta | 0.05 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and inso... [Read more]
Financial Performance
Financial StatementsNews
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalin...
Artelo Biosciences files $75M mixed securities shelf
16:46 EDT Artelo Biosciences (ARTL) files $75M mixed securities shelf
Artelo Biosciences announces collaboration with ScienceMachine
Artelo Biosciences (ARTL) announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5, or FABP5, inhibitor platform...
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea...
Artelo Biosciences announces publication of article on ART26.12
Artelo Biosciences (ARTL) announced the publication of a peer-reviewed article titled “Evaluating fatty acid-binding protein 5 as a therapeutic target for pain management” in the European Journal of P...
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year
Artelo Biosciences files to sell 9.82M shares of common stock for holders
16:23 EDT Artelo Biosciences (ARTL) files to sell 9.82M shares of common stock for holders
Artelo Biosciences regains compliance with Nasdaq
Artelo Biosciences (ARTL) announced that it has received a letter from Nasdaq confirming that the company has regained compliance with Nasdaq Listing Rule 5550, the “Equity Rule,” and Listing Rule…
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop trea...
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common...
Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?
Shares in Artelo Biosciences ($ARTL) crashed more than 23% early Monday after the American biopharma company on Friday announced plans to raise up to $31.4 million through shares and warrant…
Artelo Biosciences announces $11M private placement priced at-the-market
Artelo Biosciences (ARTL) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock and warrants to purchase up…
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggrega...
Artelo announces expansion opportunity for ART27.13 in muscle preservation
Artelo Biosciences (ARTL) announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 receptor agonist therapy. The initiative is su...
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Cal...
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and...
Artelo Biosciences files to sell 4.27M shares of common stock for holders
17:34 EDT Artelo Biosciences (ARTL) files to sell 4.27M shares of common stock for holders
Artelo Biosciences files to sell 1.64M shares of common stock
17:19 EDT Artelo Biosciences (ARTL) files to sell 1.64M shares of common stock
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glau...
Artelo announces third-party fully funded clinical study agreement for ART27.13
Artelo Biosciences (ARTL) announced it has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust. The study will evaluate the effects of Artelo...
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology
Artelo Biosciences Inc trading halted, news pending
19:50 EDT Artelo Biosciences (ARTL) Inc trading halted, news pending
Artelo Biosciences announces 3-for-1 reverse stock split
Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin…
Artelo Biosciences Announces Reverse Stock Split
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026